Non Small Cell Lung Cancer (NSCLC)

Stage I-III, Resectable

Standard Risk

Patients Scheduled for Resection

Completely Resected

ALK Mutation

CIDNA MRD Testing

None at this Time

LUN0099
Phase III Study Evaluating Safety & Pharmacokinetics of Panitumumab-IRDye800 as Optical Imaging Agent to Detect Lung Cancer During Surgical Procedures

Pl: Lui
Sponsor: Stanford University

LUN0137
SR2204: A Randomized Phase III Trial of a Perioperative Physical Activity Intervention in Older Adults with Lung Cancer and their Family Caregivers

Pl: Lui
Sponsor: City of Hope

ECOG4512
Phase III Crizotinib vs Observation in NSCLC w/ Anaplastic Lymphoma Kinase (ALK) Fusion Protein Tumors

Pl: Wakelee
Sponsor: ECOG-ACRIN

KEY

Pending
Open for Enrollment
Observational Study

Optional Path
Trial Posting
Enrollment on Hold

Extension Study
Immunotherapy

please mark up a copy using black ink and email changes to src-office@stanford.edu